Endometrial or uterine — what’s the difference?
They are used almost interchangeably, and here is why. The uterus is the whole organ. The endometrium is its inner lining. The great majority of uterine cancers begin in that lining, so "uterine cancer" and "endometrial cancer" usually describe the same disease.
The exception matters: uterine sarcomas begin in the muscle wall rather than the lining. They are uncommon, behave differently, and are treated differently. If your report says leiomyosarcoma, endometrial stromal sarcoma or carcinosarcoma, you are in a different conversation — ask your team to be explicit.
Because national statistics group them, the figures below come from SEER's combined uterine dataset. See also our Keep Uterine Cancer Away® page.
Who is at risk
- Oestrogen unopposed by progesterone is the thread through nearly all of these.
- Obesity — fat tissue produces oestrogen. The strongest modifiable risk factor, and the reason rates are rising.
- Never having been pregnant, early periods, late menopause, or polycystic ovary syndrome.
- Tamoxifen, and oestrogen-only hormone therapy in a woman who still has her uterus.
- Type 2 diabetes, high blood pressure, and age over 50.
- Lynch syndrome — up to a 40–60% lifetime risk, and endometrial cancer is often the first cancer to appear.
- Endometrial hyperplasia, especially with atypia, which is a genuine precancer and treatable as such.
- Protective: combined oral contraceptives, pregnancy, breastfeeding, physical activity and weight loss all lower risk.
Finding it early
There is no screening test — the Pap test screens for cervical cancer and does not detect endometrial cancer. Many women believe a normal Pap rules this out. It does not.
What works is taking bleeding seriously. Any bleeding after menopause is abnormal until proven otherwise — including a single episode of light spotting. About 90% of women with endometrial cancer have abnormal bleeding, usually while the cancer is still curable.
Before menopause: bleeding between periods, much heavier or longer periods, or bleeding after sex. Around perimenopause, irregular bleeding is common and usually benign — but "usually benign" is not the same as "no need to check," particularly if you carry other risk factors.
Women with Lynch syndrome are offered surveillance and, after childbearing, risk-reducing hysterectomy — the one group where active screening applies.
How it’s diagnosed
Endometrial biopsy in the clinic is the key test — a thin tube passed through the cervix to sample the lining. It takes minutes and is crampy; ask about pain relief in advance, and say if it is unbearable, because it can be done under sedation.
Transvaginal ultrasound measures the thickness of the lining and helps decide who needs a biopsy after menopause. Hysteroscopy with D&C is used when the biopsy is inconclusive or bleeding persists.
If bleeding continues despite a normal biopsy, go back. A negative sample does not close the question.
Every tumour should be tested for mismatch repair (MMR/MSI) status, and molecular classification (POLE, p53, MMR) increasingly determines how much treatment is needed.
Staging explained simply
Staged surgically, so the definitive stage follows the operation. Sentinel lymph node mapping — sampling only the first draining node — gives the same staging information with much less risk of permanent leg swelling than removing many nodes. Ask whether your surgeon uses it.
| Stage | What it means in plain words |
|---|---|
| Stage I | Confined to the body of the uterus — where most cases are found. |
| Stage II | Grown into the cervix, still inside the uterus. |
| Stage III | Beyond the uterus — ovaries, tubes, vagina or pelvic lymph nodes. |
| Stage IV | Bladder or bowel involvement, or distant spread. |
Grading and biology
Grade drives treatment here more than in many cancers. Grade 1 and 2 endometrioid cancers are oestrogen-driven, usually slow-growing, and often cured by surgery alone. Grade 3 and the non-endometrioid subtypes — serous, clear cell, carcinosarcoma — are aggressive even when they appear early and are treated far more intensively.
The newer molecular classification is genuinely changing practice: POLE-mutated cancers behave very well and may safely receive less treatment; p53-abnormal cancers need more; MMR-deficient cancers respond to immunotherapy and may signal Lynch syndrome.
Serous and clear cell subtypes are disproportionately common in Black women, which contributes to a substantially higher mortality that is not explained by biology alone — access, delays in evaluation of bleeding, and treatment differences all play a part.
How it’s treated
Surgery — hysterectomy with removal of tubes and ovaries and lymph node assessment — is the primary treatment, usually minimally invasive.
Vaginal brachytherapy is the workhorse of radiation here: three to five short outpatient sessions delivering radiation from inside the vagina, which markedly reduces recurrence at the vaginal cuff with far fewer side effects than treating the whole pelvis. External pelvic radiation, sometimes with chemotherapy, is used for higher-risk disease. For women who cannot safely have surgery, radiation alone can cure.
Chemotherapy for high-risk and advanced disease; immunotherapy has transformed MMR-deficient advanced cancer and immunotherapy combinations are now standard in advanced disease.
Fertility-sparing progestin therapy — often via an intrauterine device — is an option for carefully selected young women with early, grade 1 disease who wish to conceive, with close monitoring and definitive surgery afterwards.
Where CureRays fits: brachytherapy and pelvic radiation are our core work, and how carefully they are planned shows up years later in bowel, bladder and sexual function.
What the guidelines say
In broad strokes: stage surgically with sentinel node mapping where possible; test every tumour for MMR status; use grade, stage and molecular class to decide whether observation, vaginal brachytherapy, pelvic radiation, chemotherapy or a combination follows surgery; and treat advanced disease with chemotherapy plus immunotherapy guided by MMR status.
Your team will follow national guidelines such as those from the National Comprehensive Cancer Network (NCCN). The above is a plain-language overview of the general approach, not the guideline itself. NCCN publishes free NCCN Guidelines for Patients®.
Outcomes and odds of cure
Source: NCI SEER Cancer Stat Facts: Uterine Cancer, SEER 21 (excluding IL), 2015–2021. SEER reports endometrial cancer within its combined uterine dataset; endometrial cancer is the large majority of those cases. Figures for aggressive subtypes such as serous and clear cell are lower than these averages — ask your team for numbers matched to your grade and subtype.
| When it is found | Share of cases | 5-year relative survival |
|---|---|---|
| Localized — confined to the uterus | 67% | 95.1% |
| Regional — spread to nearby lymph nodes | 18% | 70.0% |
| Distant — spread to other organs | 11% | 19.4% |
| Unstaged | 4% | 58.8% |
These are population statistics from the National Cancer Institute's SEER program. They describe large groups of people, not any one person, and lag current treatment by several years. They cannot predict what will happen to you.
Both incidence and death rates for uterine cancer are rising — about 0.7% and 1.6% a year respectively (SEER, through 2023). That is unusual and worth knowing, not because your own outlook is worsening, but because it makes prompt evaluation of bleeding more important, not less.
Side effects and how we watch for them
Surgical menopause if the ovaries are removed before natural menopause — hot flushes, sleep disturbance, mood changes, and long-term bone and heart considerations. This warrants a real conversation about management.
Lymphoedema of the legs after extensive node removal; sentinel node mapping substantially reduces it. Report new leg swelling early — treatment works better started early.
Vaginal brachytherapy: dryness, and narrowing or shortening of the vagina. Regular dilator use or continued sexual activity genuinely prevents this — it is awkward to raise and it materially affects long-term quality of life, so we are raising it.
Pelvic radiation: diarrhoea and urinary frequency during treatment, mostly settling afterwards.
How it is assessed: graded at each visit on a standard scale.
Follow-up, remission and survivorship
Remission means no detectable cancer. Most recurrences occur within three years, most often at the vaginal cuff — which is frequently still curable when caught early, so report any new vaginal bleeding promptly.
Follow-up is chiefly examination every 3–6 months for two to three years, then annually. Routine scans are not needed for everyone.
Survivorship: menopausal symptom management, bone density, sexual health and vaginal function, lymphoedema care, and weight and diabetes management — which influence both recurrence and general health. If your tumour was MMR-deficient, pursue genetic counselling; it may matter enormously to your relatives.
Questions people actually ask
My Pap test was normal. Doesn't that rule this out?
No — and this is a common and consequential misunderstanding. The Pap test screens for cervical cancer. It does not reliably detect endometrial cancer. Abnormal bleeding needs its own evaluation regardless of Pap results.
Is endometrial cancer the same as uterine cancer?
Almost always, yes — the endometrium is the uterine lining, and most uterine cancers start there. The exception is uterine sarcoma, which starts in the muscle wall and behaves differently.
I'm overweight — did I cause this?
No. Obesity raises risk because fat tissue produces oestrogen, but risk is not blame, and plenty of women with no risk factors develop this cancer. Weight management after treatment is worth attention because it affects recurrence and overall health.
Can I keep my uterus if I want children?
Sometimes. Carefully selected young women with early, grade 1 disease may be offered progestin therapy with close monitoring instead of immediate surgery. It requires commitment to follow-up and definitive surgery afterwards, but it is a real option worth asking about.
Why is a dilator being recommended?
Radiation to the vagina can cause narrowing and scarring, which makes future examinations and sex painful. Regular dilator use or continued sexual activity keeps the tissue supple. It feels like an odd thing to be told, and it makes a real difference.
Informational only, not medical advice — confirm with your care team.
Go deeper on endometrial cancer
Read the full plain-language guide, or ask our team about vaginal brachytherapy.